Ontario’s FAST pilot showed measurable reductions in time from a positive Canada’s Drug Agency (CDA-AMC) recommendation to provincial listing for oncology medicines. BIOTECanada and Innovative Medicines Canada (IMC) reported that eligible products included in the program were listed in Ontario an average of 53 days after final CDA-AMC recommendation, compared with about 300 days under the traditional pathway in 2025. The early findings were presented as a poster at the Canadian Association for Population Therapeutics (CAPT) conference, with a reported time reduction of more than 80%. While the collaboration cautioned that more evaluation is needed as the program matures, the results provide a near-term policy benchmark for other jurisdictions weighing faster reimbursement mechanisms. For oncology operators and patient advocates, the update is concrete: it narrows the timeline where system delays can deny patients timely access to breakthrough therapies.